A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
- 13 January 2010
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 29 (3) , 467-472
Abstract
Purpose To establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and pharmacokinetic profile of ispinesib when administered as a 1-h intravenous infusion weekly for three consecutive weeks of a 28 day treatment period to patients with advanced solid tumors. Experimental Design Thirty patients were enrolled using an initial accelerated dose-escalation phase followed by a standard dose-escalation phase at doses ranging from 1–8 mg/m2/week. Pharmacokinetic samples, skin punch biopsies, and tumor biopsies (in patients with accessible tumor) were obtained during cycle 1 of treatment. Disease assessment was performed every two treatment cycles. Results The MTD was defined as 7 mg/m2 administered as a 1-h infusion weekly for three consecutive weeks of a 28 day schedule. The MTD was exceeded at 8 mg/m2 due to DLTs of grade 2 (one patient) and grade 3 neutropenia (one patient) that resulted in the inability to administer the Day 15 dose in Cycle 1. The neutrophil nadir occurred at approximately Day 8 with a 3–7 day recovery period. The most common toxicities were nausea, diarrhea, fatigue, and neutropenia. Alopecia, mucositis, and neuropathy were not observed. Stable disease was reported as the best response to treatment in nine patients. Conclusion The recommended dose of ispinesib is 7 mg/m2 over 1 h weekly for three consecutive weeks of a 28 day treatment cycle.Keywords
This publication has 20 references indexed in Scilit:
- A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumoursBritish Journal of Cancer, 2008
- Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neckInvestigational New Drugs, 2007
- A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trialInvestigational New Drugs, 2007
- An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein SynthesisMolecular and Cellular Biology, 2007
- Development of new cancer therapeutic agents targeting mitosisExpert Opinion on Investigational Drugs, 2006
- The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinksNature, 2005
- Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal CarcinomaJournal of Clinical Oncology, 2004
- A bipolar kinesinNature, 1996
- Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivoCell, 1995